When a physician prescribes a specialty drug, the first operational question is not whether the drug requires prior authorization. It is which benefit — pharmacy or medical — covers the drug for this patient under this plan. The answer determines which entity processes the claim, which coding system is used, which formulary applies, and which prior authorization pathway the provider or hub team must navigate. Getting this wrong at the benefit verification stage cascades into denied claims, delayed therapy, and wasted administrative resources.
This article is for hub and patient-services leads, specialty pharmacy operations managers, provider office staff, and manufacturer support program designers who need to understand why benefit verification for specialty drugs is more complex than for traditional medications and what to build into the workflow to prevent pathway errors.
Pharmacy benefit versus medical benefit: the structural difference
Pharmacy benefit
Under the pharmacy benefit, a prescription is sent to a pharmacy — retail, specialty, or mail-order — and the pharmacy dispenses the drug to the patient. The claim is adjudicated in real time using the NCPDP Telecommunication Standard. The drug is identified by its National Drug Code (NDC), and the pharmacy bills the payer or pharmacy benefit manager (PBM) for the drug cost plus a dispensing fee.
Key characteristics:
- Claims processed via NDC-level billing at point of dispensing.
- Formulary management by the PBM: tier placement, step therapy, preferred drug lists.
- Prior authorization submitted to the PBM, usually electronically through platforms like CoverMyMeds.
- Specialty pharmacy network restrictions may limit which pharmacies can dispense the drug.
- Patient cost sharing is typically a copay or coinsurance applied at pickup, immediately credited toward deductible and out-of-pocket maximum.
Medical benefit
Under the medical benefit, the drug is administered by or under the supervision of a healthcare provider — typically in a physician office, infusion center, or hospital outpatient department. The provider acquires the drug (buy-and-bill) or receives it from a specialty pharmacy (sourced or delivered), administers it, and then bills the payer separately for the drug and the administration service.
Key characteristics:
- Claims processed using Healthcare Common Procedure Coding System (HCPCS) codes, typically J-codes for drugs and CPT codes for administration.
- Drug billed by the provider or facility, not by a pharmacy.
- Prior authorization submitted to the medical benefit reviewer — often a separate entity from the PBM's pharmacy benefit reviewer.
- Patient cost sharing is typically coinsurance, calculated after the claim is processed, and applied toward the medical deductible and out-of-pocket maximum.
- Reimbursement based on ASP + a percentage (Medicare Part B) or payer-specific fee schedules.
The gray zone: dual-benefit drugs
Some specialty drugs can be covered under either benefit depending on the plan. BRG's analysis of medical versus pharmacy benefit pathways notes that certain self-injectable biologics — such asHumira, Dupixent, and other agents that patients can self-administer — may be covered under the medical benefit in some employer-based plans even though they are typically pharmacy-benefit drugs. This is not consistent across plans or payers.
A payer may also change the benefit pathway for the same drug mid-year. BlueCross BlueShield of South Carolina, for example, notes that "certain self-administered drugs aren't covered under the medical benefit" but provides exceptions for hematologists, oncologists, nephrologists, and rheumatologists who "may continue to bill for these drugs under the medical benefit."
Why benefit verification fails for specialty drugs
Manual, phone-based processes
The NCPDP Specialty Pharmacy Benefit Coverage Identification White Paper documented that verifying coverage for a specialty medication often requires checking both the pharmacy benefit and the medical benefit — a "duplicate benefit investigation" that typically involves phone calls exceeding 30 minutes, multiple transfers, and inconsistent information from payer representatives.
Surescripts reported in its 2025 Annual Impact Report (published April 2026) that the average manual benefit verification takes approximately 17 minutes, compared to under 3 seconds for an electronic transaction. But electronic benefit verification through Surescripts covers pharmacy benefit data primarily; medical benefit verification for buy-and-bill drugs often still requires direct contact with the payer's medical benefit review unit.
Different prior authorization pathways
When a drug is covered under the pharmacy benefit, prior authorization is submitted to the PBM's pharmacy review team using the drug's NDC and supported by clinical documentation from the prescriber. When the same drug is covered under the medical benefit, prior authorization is submitted to the payer's medical benefit review team using HCPCS J-codes and supported by clinical documentation formatted for medical necessity review.
UnitedHealthcare's Specialty Pharmacy Medical Benefit Management program, managed through Optum, has a separate prior authorization process for medical benefit injectable medications that is distinct from the pharmacy benefit prior authorization managed through the PreCheck MyScript tool. Submitting a medical benefit prior auth to the pharmacy review team — or vice versa — results in a denial, not a redirect.
Different formularies and clinical criteria
A payer may place a drug on a preferred tier under the pharmacy benefit formulary but require step therapy under the medical benefit policy — or exclude it entirely from one pathway while covering it under the other. XiFin noted in its 2025 analysis of specialty pharmacy evolution that "the move to medical benefit billing is reshaping how pharmacies must operate" because the coding, benefit verification, and prior authorization requirements under the medical benefit are fundamentally different from pharmacy benefit workflows.
Site-of-care requirements
Many payers enforce site-of-care edits that determine where a drug can be administered based on the benefit pathway. A biologic covered under the medical benefit may only be approved for administration in a physician office or infusion center, not in a hospital outpatient department, because the reimbursement rate differs. BlueCross BlueShield of South Carolina notes that "drugs with a site-of-care requirement may only be approved in certain sites of care or if the patient is under 18 years of age."
If benefit verification identifies the wrong pathway, the site-of-care edit may be applied incorrectly, resulting in a denial at the point of claim submission — after the drug has already been acquired and administered.
The benefit verification workflow for specialty drugs
Step 1: Determine the likely benefit pathway
Before initiating verification, the hub team or provider office should determine which benefit pathway is most likely based on:
| Factor | Pharmacy Benefit More Likely | Medical Benefit More Likely |
|---|---|---|
| Route of administration | Self-injectable, oral | IV infusion, injectable administered by provider |
| Site of care | Patient's home, retail pharmacy | Physician office, infusion center, hospital outpatient |
| Payer type | Commercial with PBM management | Medicare Part B, commercial medical benefit carve-out |
| Drug class | Self-administered biologics, oral oncology | Infusion biologics, buy-and-bill drugs |
| Plan-specific rules | Standard PBM formulary | Employer carve-out, medical benefit drug list |
Step 2: Run dual-benefit verification
Because the same drug can be covered under either benefit for a given patient, the verification step should check both pathways. This means:
Pharmacy benefit check: Submit an electronic benefit verification query (through Surescripts or equivalent) to determine if the drug is on the pharmacy formulary, what tier it is on, whether prior authorization is required, and what the patient's copay or coinsurance will be.
Medical benefit check: Contact the payer's medical benefit review unit (often a separate phone line from pharmacy) to determine if the drug is covered under the medical benefit, what HCPCS code applies, what the reimbursement rate is, and whether prior authorization or medical necessity review is required.
Compare: If both pathways cover the drug, compare the patient's out-of-pocket cost under each pathway, the prior authorization requirements, the specialty pharmacy or sourcing requirements, and the site-of-care restrictions. Select the pathway that provides the fastest access at the lowest patient cost.
Step 3: Initiate prior authorization through the correct pathway
Once the benefit pathway is confirmed, submit the prior authorization to the correct reviewer:
Pharmacy benefit PA: Submit electronically through the PBM's portal or CoverMyMeds. Use the drug's NDC. Include clinical documentation supporting the diagnosis, prior therapies tried, and any step-therapy requirements.
Medical benefit PA: Submit to the payer's medical benefit review team (Optum for UnitedHealthcare, Prime Therapeutics for EmblemHealth starting January 2026, etc.). Use the correct HCPCS J-code. Include medical necessity documentation, site-of-care justification, and any applicable clinical policy criteria.
Point-of-Care Partners documented that a traditional phone-based medical benefit prior authorization form can contain more than 50 questions in random order, not customized to the diagnosis — compared to web-based portals that present diagnosis-specific clinical criteria questions and can generate immediate authorization when criteria are met.
EmblemHealth's 2026 provider manual notes that Prime Therapeutics now performs utilization management for "all drugs, including home infusion therapy, specialty pharmacy, chemotherapy, and supportive agents" and that "only codes that are included on the Medical Drug Preauthorization list hosted on Prime Therapeutics' GatewayPA site will require preauthorization for home infusion." These payer-level changes are frequent: Colorado Medicaid, for example, transitioned its PBM vendor from Prime Therapeutics to MedImpact in April 2026, requiring provider offices to update billing contacts and PA submission workflows mid-year.
Step 4: Confirm patient cost sharing and apply assistance
Patient cost sharing differs significantly between benefit pathways:
- Pharmacy benefit: Copay or coinsurance is calculated at point of dispensing and applied toward the pharmacy deductible and out-of-pocket maximum. Manufacturer copay cards can often be applied directly.
- Medical benefit: Coinsurance is calculated after claim adjudication, which may take weeks. The patient may not know their exact cost sharing until the Explanation of Benefits is processed. Copay assistance programs may need to reimburse the patient retroactively rather than paying at point of service.
LUX Infusion noted in its 2025 guide to specialty drug coverage that "when covered under the pharmacy benefit, associated out-of-pocket costs are immediately applied toward the deductible and max out-of-pocket. Under the medical benefit, the claim submitted by the provider's office undergoes review before it is approved. This can take time, and associated out-of-pocket expenses take longer to be applied toward a patient's deductible and max out-of-pocket."
Operational traps that delay therapy
1. Verifying only one benefit pathway
If the hub team checks only the pharmacy benefit and the drug is actually covered under the medical benefit for this patient's plan, the prior authorization will be submitted to the wrong reviewer. The denial will trigger a rework cycle that adds 5–15 business days to time-to-therapy.
2. Using the wrong coding system
Submitting a pharmacy benefit claim with an HCPCS J-code, or a medical benefit claim with an NDC, will result in an automatic rejection. The NCPDP white paper documented that "these multiple billing processes can lead to unexpected financial ramifications for the patient, provider and payer."
3. Missing specialty pharmacy network restrictions
If the drug is covered under the pharmacy benefit but the payer requires use of a specific specialty pharmacy network (e.g., Accredo for certain EmblemHealth plans, CVS Specialty for SmartHealth), dispensing through an out-of-network pharmacy will result in a denied claim — even if prior authorization was approved.
4. Ignoring reverification timing
Patient benefit information changes at the start of each plan year, and sometimes mid-year if the employer changes plan designs. Surescripts offers batch reverification for up to 50,000 patients at once, but many hub teams still rely on individual manual checks that miss coverage changes.
5. Not confirming site of care before administration
A provider who administers a buy-and-bill drug in a hospital outpatient department when the payer's site-of-care edit requires physician office administration will receive a reduced reimbursement or a full denial. The financial loss falls on the provider, not the patient.
What manufacturer support programs should build
Dual-benefit verification as a default
Every benefit investigation for a specialty drug should check both the pharmacy benefit and the medical benefit as a standard workflow. This is not optional for drugs that can be administered in multiple settings or covered under either pathway.
Coding intelligence for hub teams
Hub teams need access to both the NDC (for pharmacy benefit claims) and the HCPCS J-code (for medical benefit claims) for every drug in the support program. The coding should be verified against the payer's current medical drug list, not assumed from the FDA-approved label.
Prior authorization routing by benefit pathway
Hub teams should maintain a routing table that maps each major payer to the correct PA submission pathway (pharmacy portal versus medical benefit reviewer) for each drug. This table should be updated quarterly, because payers frequently change their PA processes — as EmblemHealth did in January 2026 when it moved medical benefit preauthorization to Prime Therapeutics.
Patient cost-sharing estimation under both pathways
The hub should provide the patient with an estimated out-of-pocket cost under both the pharmacy benefit and the medical benefit before the drug is dispensed or administered, so the patient can make an informed decision and so copay assistance can be applied through the correct channel.
What to monitor next
- Payer consolidation of medical and pharmacy benefit PA: UnitedHealthcare's use of Optum for medical benefit PA and PreCheck MyScript for pharmacy benefit PA creates two separate workflows for the same drug. Watch for payers that consolidate these into a single portal.
- Electronic medical benefit verification: Surescripts and other platforms are expanding electronic verification beyond pharmacy benefit data. As medical benefit verification becomes available electronically, the phone-based dual-verification step should shrink.
- Site-of-care policy changes: Payers are increasingly restricting where infusion biologics can be administered. Verify site-of-care requirements at the time of each new patient intake, not just at initial benefit verification.
- White bagging and brown bagging mandates: Some payers require that medical benefit drugs be sourced through a designated specialty pharmacy rather than purchased by the provider. These mandates affect the benefit verification workflow and the provider's buy-and-bill economics.
Sources
- 42 CFR 414.904: Medicare Part B drug payment methodology, ASP-based reimbursement. Available at https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-J/section-414.904.
- 42 CFR 414.910: Medicare Part B drug payment limit files, ASP quarterly publication schedule. Available at https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-J.
- CMS, Medicare Part B Drug Average Sales Price (ASP) Data Collection and Reporting Guidance: ASP data submission requirements and quarterly payment limit files. Available at https://www.cms.gov/medicare/payment/part-b-drugs/average-sales-price-asp.
- Federal Register, CY 2026 PFS Final Rule (October 31, 2025): ASP calculation changes, bona fide service fee documentation requirements. Available at https://www.federalregister.gov/documents/2025/10/31/2025-23687/medicare-program-cy-2026-revisions-to-payment-policies-under-the-physician-fee-schedule-and-other.
- NCPDP Specialty Pharmacy Benefit Coverage Identification White Paper: Dual benefit investigation workflow, coding system differences.
- Surescripts Annual Impact Report 2025 (April 2026): Electronic benefit verification transaction volume and timing.
- Surescripts Electronic Benefit Verification product documentation: Batch reverification, real-time verification capabilities.
- BRG, "The Medical versus the Pharmacy Benefit: An Overview": Product acquisition, dispensing, and claims processing under each benefit.
- XiFin, "The Specialty Pharmacy Evolution: Succeeding in the Shift to Medical Benefit Pathways" (September 2025): Coding, prior authorization, and denial management for medical benefit specialty drugs.
- LUX Infusion, "Understanding Specialty Drug Coverage: Medical vs Pharmacy Benefit" (2025): Patient cost sharing differences between benefit pathways.
- BlueCross BlueShield of South Carolina, Provider Pharmacy Services: Medical benefit drug lists, site-of-care requirements, self-administered drug exceptions.
- EmblemHealth Provider Manual, Pharmacy Services and Specialty Pharmacy (2026): Prime Therapeutics utilization management, medical drug preauthorization requirements.
- UnitedHealthcare, Specialty Pharmacy – Medical Benefit Management: Optum-managed prior authorization for medical benefit injectable medications.
- SmartHealth 2026 Provider Manual: Medical benefit specialty drug prior authorization and buy-and-bill workflow.
